Where’s Upton? 21st Century Cures Take Temporary Back Seat To The Internet
This article was originally published in The Gray Sheet
Executive Summary
Republicans dominate first official 21st Century Cures hearing, but Net Neutrality forces many members to choose, and the initiative’s leader makes quick exit.
You may also be interested in...
Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill
CDRH Director Jeffrey Shuren participated in the first roundtable of a newly launched House Energy and Commerce Committee initiative to accelerate drug and device development. He emphasized the device center’s recent proposals to minimize pre-market data collection with postmarket controls, and supported the promise of clinical trial networks.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.